View ValuationMarvel Biosciences 将来の成長Future 基準チェック /06現在、 Marvel Biosciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 18Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingOn April 17, 2026, Marvel Biosciences Corp closed the transaction.お知らせ • Apr 17Marvel Biosciences Corp. and Marvel Biotechnology Inc Identify Liquid Formulations for Neurodevelopmental DisordersMarvel Biosciences Corp., and its wholly-owned subsidiary, Marvel Biotechnology Inc. announced it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess: Well accepted clinic ready excipients; A high concentration/low volume dosing solution; A simple, economic manufacturing process; Long term stability at room temperature; High oral bioavailability. Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism pre-clinical studies. We actually achieved 79 and 91% oral bioavailability (F%), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our Phase I trial, but also builds additional intellectual property around MB-204. The identification of a pediatric-friendly liquid formulation is another milestone in Marvel’s development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the Company’s intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel’s transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points.お知らせ • Dec 08Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026.お知らせ • May 13Marvel Biosciences Corp. announced that it has received CAD 1.01875 million in fundingOn May 12, 2025. Marvel Biosciences Corp. has closed the transaction. It has issued 8,150,000 units at a price of CAD 0.125 per Unit for aggregate gross proceeds of CAD 1,018,750.お知らせ • Mar 29Marvel Biosciences Corp. announced that it expects to receive CAD 1.5 million in fundingMarvel Biosciences Corp. announces a non-brokered private placement of up to 12,000,000 units at a price of CAD 0.125 per unit for gross proceeds of CAD 1,500,000 on March 28, 2025. Each Unit will be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.175 per share. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offeringお知らせ • Jan 08Marvel Biosciences Corp. announced that it expects to receive CAD 2.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it will issue up to 16,666,667 common shares of the company at a price of CAD 0.15 per common share for the gross proceeds of up to CAD 2,500,000.05 on January 7, 2025. The closing of the offering may occur in one or more tranches, the first of which is expected to close on or about February 14, 2025. The closing of the offering is subject to the receipt of all regulatory approvals, including the approval of the TSX Venture Exchange, and will occur within 45 days from the date hereof. The securities offered under the listed issuer financing exemption will not be subject to a hold period, pursuant to applicable Canadian securities laws.お知らせ • Nov 25Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025.お知らせ • Oct 13Marvel Biosciences Shares Positive Results of Mb204 in the Oprm1 Model of AutismMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the Oprm1 mouse model of autism (widely used to study social behavior deficits). Marvel reported that just one hour after administering a single oral dose of MB204, the drug successfully reversed the social behaviour deficits typically seen in the model. Key Highlights: A high dose of MB204 (2.5 mg/kg) significantly restored social behaviour in all measured endpoints (p<0.0001). Improvements were seen in social interaction behaviours including, the number and duration of nose contacts, the number and duration of paw contacts, and time spent self-grooming, amongst others. A lower dose of MB204 (1 mg/kg) also reversed nearly all social behaviour deficits, showing a clear connection between dose and response. The higher dose of MB204 not only improved/restored social interactions in Oprm1 (autistic) mice, but even outperformed the social interactions of normal (non-autistic) mice on several endpoints, demonstrating MB204's potent pro- social effect. Currently, Drs. Le Merrer and Becker are now testing MB204 in another chronic Rett syndrome model (Mecp2) and are looking forward to seeing how it performs 'head-to-head' against the approved drug Trofinetide.お知らせ • May 17Marvel Biosciences Corp. announced that it expects to receive CAD 1 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement of up to 10,000,000 units at a price of CAD 0.10 per unit for the gross proceeds of CAD 1,000,000 on May 16, 2024. Each Unit will be comprised of one common share and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.15 per share on the date that is two years from the date of the issuance. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering payable in cash, plus finder’s warrants in an amount equal to up to 7% of the aggregate number of Units, with each Finder’s Warrant being exercisable to acquire one common share at a price of CAD 0.15 per share until two years following the issuance of the Finder’s Warrants. The Common Shares and the Warrants are subject to a hold period and resale restriction in Canada that expires four months plus one day from the issuance of the Units and such other restrictions as imposed under applicable securities legislation. The Offering is subject to acceptance by the TSX Venture Exchange.お知らせ • Jan 21Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it has issued unsecured convertible debentures for the gross proceeds of CAD 500,000 on January 19, 2024. The Debentures will mature 3 years following the date of issuance and will bear interest at a rate of twelve percent 12% per annum , payable annually in arrears. Interest may be repaid in cash or common shares, at the option of the company, based on the 20-day volume weighted average trading price of the common shares on the TSX Venture Exchange, calculated 3 days prior to the payment date, subject to the minimum price permitted by the TSX Venture Exchange. In the event that the volume weighted average trading price of the common shares on the TSX Venture Exchange is at least CAD 0.60 per share for a period of 10 consecutive trading days, at any time during the term of the debentures, the company shall have the right, at its discretion, to require the holder of the debentures to convert the outstanding principal amount into common shares at the conversion price. The company did not pay any commission, finder’s fee, or similar payment in connection with the offering. Pursuant to applicable Canadian securities laws, the debentures, as well as any underlying common shares to be issued upon conversion or exchange of these securities, are subject to a hold period of four months and one day. The Private Placement remains subject to the final approval of the TSX Venture Exchange.お知らせ • Oct 28Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024.お知らせ • Aug 23Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human TrialsMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving the way for Phase 1 human trials to begin. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Marvel Biosciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:MBCO.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数1/31/2026N/A-2-1-1N/A10/31/2025N/A-2-1-1N/A7/31/2025N/A-2-1-1N/A4/30/2025N/A-2-1-1N/A1/31/2025N/A-2-1-1N/A10/31/2024N/A-1-1-1N/A7/31/2024N/A-2-1-1N/A4/30/2024N/A-2-1-1N/A1/31/2024N/A-3-1-1N/A10/31/2023N/A-3-1-1N/A7/31/2023N/A-2-1-1N/A4/30/2023N/A-2-1-1N/A1/31/2023N/A-2-1-1N/A10/31/2022N/A-2-2-2N/A7/31/2022N/A-3-2-2N/A4/30/2022N/A-4-2-2N/A1/31/2022N/A-4-2-2N/A10/31/2021N/A-3-1-1N/A7/31/2021N/A-3-1-1N/A4/30/2021N/A-1-1-1N/A1/31/2021N/A-1-1-1N/A10/31/2020N/A-1-1-1N/A7/31/2020N/A-1-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MBCO.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: MBCO.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: MBCO.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: MBCO.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: MBCO.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MBCO.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 23:36終値2026/05/21 00:00収益2026/01/31年間収益2025/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Marvel Biosciences Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 18Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingOn April 17, 2026, Marvel Biosciences Corp closed the transaction.
お知らせ • Apr 17Marvel Biosciences Corp. and Marvel Biotechnology Inc Identify Liquid Formulations for Neurodevelopmental DisordersMarvel Biosciences Corp., and its wholly-owned subsidiary, Marvel Biotechnology Inc. announced it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess: Well accepted clinic ready excipients; A high concentration/low volume dosing solution; A simple, economic manufacturing process; Long term stability at room temperature; High oral bioavailability. Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism pre-clinical studies. We actually achieved 79 and 91% oral bioavailability (F%), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our Phase I trial, but also builds additional intellectual property around MB-204. The identification of a pediatric-friendly liquid formulation is another milestone in Marvel’s development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the Company’s intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel’s transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points.
お知らせ • Dec 08Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026.
お知らせ • May 13Marvel Biosciences Corp. announced that it has received CAD 1.01875 million in fundingOn May 12, 2025. Marvel Biosciences Corp. has closed the transaction. It has issued 8,150,000 units at a price of CAD 0.125 per Unit for aggregate gross proceeds of CAD 1,018,750.
お知らせ • Mar 29Marvel Biosciences Corp. announced that it expects to receive CAD 1.5 million in fundingMarvel Biosciences Corp. announces a non-brokered private placement of up to 12,000,000 units at a price of CAD 0.125 per unit for gross proceeds of CAD 1,500,000 on March 28, 2025. Each Unit will be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.175 per share. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering
お知らせ • Jan 08Marvel Biosciences Corp. announced that it expects to receive CAD 2.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it will issue up to 16,666,667 common shares of the company at a price of CAD 0.15 per common share for the gross proceeds of up to CAD 2,500,000.05 on January 7, 2025. The closing of the offering may occur in one or more tranches, the first of which is expected to close on or about February 14, 2025. The closing of the offering is subject to the receipt of all regulatory approvals, including the approval of the TSX Venture Exchange, and will occur within 45 days from the date hereof. The securities offered under the listed issuer financing exemption will not be subject to a hold period, pursuant to applicable Canadian securities laws.
お知らせ • Nov 25Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025.
お知らせ • Oct 13Marvel Biosciences Shares Positive Results of Mb204 in the Oprm1 Model of AutismMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the Oprm1 mouse model of autism (widely used to study social behavior deficits). Marvel reported that just one hour after administering a single oral dose of MB204, the drug successfully reversed the social behaviour deficits typically seen in the model. Key Highlights: A high dose of MB204 (2.5 mg/kg) significantly restored social behaviour in all measured endpoints (p<0.0001). Improvements were seen in social interaction behaviours including, the number and duration of nose contacts, the number and duration of paw contacts, and time spent self-grooming, amongst others. A lower dose of MB204 (1 mg/kg) also reversed nearly all social behaviour deficits, showing a clear connection between dose and response. The higher dose of MB204 not only improved/restored social interactions in Oprm1 (autistic) mice, but even outperformed the social interactions of normal (non-autistic) mice on several endpoints, demonstrating MB204's potent pro- social effect. Currently, Drs. Le Merrer and Becker are now testing MB204 in another chronic Rett syndrome model (Mecp2) and are looking forward to seeing how it performs 'head-to-head' against the approved drug Trofinetide.
お知らせ • May 17Marvel Biosciences Corp. announced that it expects to receive CAD 1 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement of up to 10,000,000 units at a price of CAD 0.10 per unit for the gross proceeds of CAD 1,000,000 on May 16, 2024. Each Unit will be comprised of one common share and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.15 per share on the date that is two years from the date of the issuance. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering payable in cash, plus finder’s warrants in an amount equal to up to 7% of the aggregate number of Units, with each Finder’s Warrant being exercisable to acquire one common share at a price of CAD 0.15 per share until two years following the issuance of the Finder’s Warrants. The Common Shares and the Warrants are subject to a hold period and resale restriction in Canada that expires four months plus one day from the issuance of the Units and such other restrictions as imposed under applicable securities legislation. The Offering is subject to acceptance by the TSX Venture Exchange.
お知らせ • Jan 21Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it has issued unsecured convertible debentures for the gross proceeds of CAD 500,000 on January 19, 2024. The Debentures will mature 3 years following the date of issuance and will bear interest at a rate of twelve percent 12% per annum , payable annually in arrears. Interest may be repaid in cash or common shares, at the option of the company, based on the 20-day volume weighted average trading price of the common shares on the TSX Venture Exchange, calculated 3 days prior to the payment date, subject to the minimum price permitted by the TSX Venture Exchange. In the event that the volume weighted average trading price of the common shares on the TSX Venture Exchange is at least CAD 0.60 per share for a period of 10 consecutive trading days, at any time during the term of the debentures, the company shall have the right, at its discretion, to require the holder of the debentures to convert the outstanding principal amount into common shares at the conversion price. The company did not pay any commission, finder’s fee, or similar payment in connection with the offering. Pursuant to applicable Canadian securities laws, the debentures, as well as any underlying common shares to be issued upon conversion or exchange of these securities, are subject to a hold period of four months and one day. The Private Placement remains subject to the final approval of the TSX Venture Exchange.
お知らせ • Oct 28Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024.
お知らせ • Aug 23Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human TrialsMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving the way for Phase 1 human trials to begin. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration.